AddLife AB (publ) (ADDLF) Q2 2026 Earnings Call Transcript

AddLife reported Q2 2026 group EBITA margin of 12.6%, up from 11.9% a year earlier (+70 bps), with improvements in both Labtech (13.4%, +100 bps) and Medtech (12.8%). Management highlighted positive sales momentum driven by advanced products, while noting Spain strikes and subdued U.K. capital spending weighed on revenue. Overall, the call emphasized a clear margin improvement trend and improving performance in Home Care and Eye Surgery.

Analysis

The key signal is not the modest topline improvement; it is that the margin engine is still moving up while end-market noise remains mixed. For a distribution-heavy healthcare platform, that usually means pricing discipline, mix shift, and cost absorption are all working at once, which can drive EPS faster than revenue and justify multiple expansion if it persists for 2-3 quarters. The market is likely underestimating how much of this is self-help versus cyclical recovery.

Second-order, the winners are the higher-spec product suppliers and the businesses inside the portfolio with recurring service/consumable attach, because management will keep prioritizing advanced products that support gross margin and turn. The losers are lower-value commodity lines and smaller regional competitors that cannot match breadth, procurement terms, or cross-sell; if this mix shift continues, AddLife can slowly take share without needing outsized volume growth. That also makes the portfolio look less like a pure capex beta and more like a quality compounder.

The near-term risk is that Spain labor disruptions and weak UK spending stay visible into the next print, making this look like a margin beat with soft demand underneath. The thesis is falsified if Q3 shows margin reverting below roughly 12% or if organic growth stays anaemic despite continued improvement actions; then this becomes a cost-control story, not a structural rerating story. Over 6-18 months, the upside case is sustained 12.5%+ EBITA margins and a steadier mix of advanced products, which should support a higher multiple even if top-line growth remains mid-single digit.

Key Decisions for Investors

• Buy ADDLF on any 2-4% post-earnings pullback; target 8-12% upside over 3-6 months if the next quarter confirms EBITA margin stays above 12.5% and organic sales stabilize. Invalidate if margin slips back below 12.0% or the revenue trend deteriorates further.
• Pair trade: long ADDLF / short GETI B over the next 1-3 months as a relative-quality expression. ADDLF has more visible self-help and mix benefits; GETI B remains more exposed to capex cyclicality and execution noise. Cut the trade if Getinge shows accelerating orders or AddLife loses margin momentum.
• Set a watch alert for the next quarterly print rather than chasing the move now. If Spain/UK headwinds persist without offsetting order improvement, take profits on any rerating; if those headwinds fade, hold for a 6-18 month compounding thesis.
• If you need a lower-risk expression, use ADDLF as a cash equity position rather than options; the signal is medium-term operating improvement, not a binary event. Options look unattractive unless implied volatility remains depressed into the next results window.